Using NGS to study the microbiome of joints will enhance our understanding of orthopedic diseases in general and orthopedic infections in particular. This is science moving the clinical practice to another realm.
ORLANDO, Fla. (PRWEB) November 08, 2019
MicroGenDX Laboratories, the world leader in providing Next Generation DNA Sequencing (NGS) in microbial identification, equipped a groundbreaking multicenter study with its gold standard NGS test to be featured at American Association of Hip and Knee Surgeons (AAHKS). Renowned orthopedic surgeon Javad Parvizi, MD will take the podium multiple times to discuss results of the paramount study “Reinfection or Persistence of Periprosthetic Joint Infection? Next generation sequencing Reveals New Findings."
“NGS is revolutionizing the microbial diagnosis of chronic infections in orthopedics” says Javad Parvizi, MD. “Using NGS to study the microbiome of joints will enhance our understanding of orthopedic diseases in general and orthopedic infections in particular. This is science moving the clinical practice to another realm.”
Surgical management of PJI remains challenging with patients failing treatment despite best efforts. The multicenter study hypothesized that some of these failures, if not the majority, are the result of an organism that was present at the time of initial surgery. This phenomenon of persistence was investigated with the help of MicroGenDX Next-Generation DNA Sequencing.
“New advancements in microbial diagnostics should be supported by high quality medical evidence,” says MicroGenDX CEO, Rick Martin. “We are committed to supporting clinical trials that demonstrate NGS is superior to traditional culture techniques so that this technology can help patients overcome these devastating infections.”
Dr. Parvizi will take the podium multiple times at AAHKS to discuss the exciting findings of this study and the implications for future treatment of recurring orthopedic infections.
“NGS is one of the most important advances that medicine has seen in the recent decade,” says Dr. Parvizi. “Data from orthopedics and other surgical disciplines has demonstrated that NGS has been transformative in the management of patients with infections. We have a new gold standard in antimicrobial treatment that has shown to substantially improve outcome.”
Those attending AAHKS can find MicroGenDX at booth #1117 to learn more about this revolutionary technology and how to gain access to its laboratory services.
MicroGenDX is a CAP accredited and CLIA certified molecular diagnostic lab and is the leader in providing the gold standard of microbial diagnostics via DNA technology: Next Generation DNA Sequencing (NGS), qPCR and Resistance Gene detection. Through the utilization of a curated database of 50,000+ microbial species DNA Sequence codes, MicroGenDX provides clinicians and their patients with the most informative microbial diagnostic testing that science can offer; resulting in better outcomes.
Unlike the traditional culturing of samples, Next Generation DNA Sequencing is able to extract the microbial DNA from the sample you provide and report precisely what the patient is dealing with via NGS technology versus what a lab was able to grow. This technology allows for faster and more accurate diagnostics resulting in improved treatment and healing times in clinical outcomes.
MicroGenDX has over 10 years experience running more NGS samples – over 400,000 and counting -- than any laboratory in the world. The laboratory location in Lubbock Texas MicroGenDX is led by a team of molecular biologists, biochemists, and physicians.
To learn more information, visit http://www.microgendx.com.